Phase 2RecruitingPriority 3 · Moderate priorityNCT06716658
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Plain-language summary
This Phase 2 trial is evaluating JAK1 Inhibitor as a treatment for people newly diagnosed with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
JAK1 Inhibitor (DRUG): Golidocitnib 150mg QD orally, with a 28-day cycle. Efficacy will be evaluated once per cycle during the first year, and once every two cycles thereafter. Treatment will continue for up to 24 cycles, or until disease progression, lack of response within the first 6 cycles, or the occurrence of intolerable toxicity, whichever occurs first
- Drugs / treatments
- JAK1 Inhibitor
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details